In the NSCLC discovery set, a four-gene IFNγ-positive (IFNγ+) signature comprising IFNγ, CD274, LAG3, and CXCL9 was associated with higher overall response rates, longer median progression-free survival, and overall survival compared with signature-low patients. IFNγ+-signature NSCLC patients had improved survival regardless of IHC PD-L1 status...The ORR in NSCLC patients was approximately 6- or 4-fold higher in patients with IFNγ sig+ or PD-L1–positive (PD-L1+) tumors, respectively, compared with those who were negative for these two biomarkers...